What is the current stock price of Harrow Health, Inc. (HROW)?

As of the latest market data, Harrow Health, Inc. (HROW) is trading at $35.93. The stock has seen a loss of -3.65% today.

Does Harrow Health, Inc. (HROW) pay a dividend?

Based on current data, Harrow Health, Inc. does not have a confirmed active dividend policy.

What is the market cap of Harrow Health, Inc.?

The current market capitalization of Harrow Health, Inc. (HROW) is approximately unavailable.

HROW

Harrow Health, Inc.·Healthcare

35.93

3.647%(−1.36)

Market Closed

37.83

5.288%(+1.90)

After Hours

Last Updated: — ET

52W L: $21.1252W H: $54.85

HROW NEWS

defenseworld.net

3d ago

JPMorgan Chase & Co. Sells 42,246 Shares of Harrow, Inc. $HROW

JPMorgan Chase and Co. lowered its position in Harrow, Inc. (NASDAQ: HROW) by 53.9% during the undefined quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 36,167 shares of the company's stock after selling 42,246 shares during the quarter. JPMorgan Chase and Co. owned

globenewswire.com

Mar 24

Harrow Announces Pricing of $50.0 Million Offering of Senior Unsecured Notes Due 2030

NASHVILLE, Tenn., March 24, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the pricing of its private offering (the “Offering”) of $50.0 million aggregate principal amount of 8.625% senior unsecured notes due 2030 (the “2030 Notes”).

fool.com

Mar 24

A Major Investor Just Sold $7.8 Million in Harrow Stock -- Is This a Sell Signal?

Opaleye Management Inc. disposed of 198,572 shares indirectly across two days, with a transaction value of roughly $7.8 million based on weighted average prices of $39.15 on March 3 and $39.67 on March 4. Following the transactions, Opaleye Management Inc. retains an indirect position of approximately 3.68 million shares across both vehicles.

globenewswire.com

Mar 24

Harrow Announces Add-On Offering of $50.0 Million of Senior Unsecured Notes to Support Growth

NASHVILLE, Tenn., March 24, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it intends to offer, subject to market and certain other conditions, an additional $50.0 million in aggregate principal amount of its 8.625% senior unsecured notes due 2030 (the "2030 Notes"). The 2030 Notes will be guaranteed on a senior unsecured basis by the Company's existing and future wholly-owned domestic restricted subsidiaries and any of its other restricted subsidiaries that guarantees or co-issues any of its indebtedness or any indebtedness of any of its subsidiaries that guarantees the 2030 Notes, subject to certain exceptions. The 2030 Notes will be issued as additional notes under the same indenture governing the $250,000,000 aggregate principal amount of 2030 Notes that were issued on September 12, 2025 (the “Existing Notes”), will be treated as a single series with the Existing Notes and will have the same terms as the Existing Notes other than with respect to the date of issuance and the issue price.

globenewswire.com

Mar 18

Harrow Announces Three Abstracts Accepted for Presentation at ASCRS 2026 Annual Meeting

NASHVILLE, Tenn., March 18, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that three scientific abstracts highlighting its commercial products VEVYE® (cyclosporine ophthalmic solution) 0.1% and ILEVRO® (nepafenac ophthalmic suspension) 0.3% have been accepted for presentation at the American Society of Cataract and Refractive Surgery (ASCRS) 2026 Annual Meeting, taking place April 10–13 at the Walter E. Washington Convention Center in Washington, D.C.

seekingalpha.com

Mar 17

Harrow Emerging As Dominant Operator In U.S. Ophthalmic Market

Harrow, Inc. is rapidly evolving into a dominant US ophthalmic pharma player, with a 30-fold revenue increase since 2015 and strong operating leverage. HROW's recent 35% stock pullback post-Q4 2025 is attributed to conservative 2026 guidance, not deteriorating fundamentals, presenting a compelling buying opportunity. Vevye and Iheezo, HROW's flagship drugs, are set for significant revenue acceleration through expanded insurance coverage, salesforce doubling, and clinical trial catalysts.

Company Profile

Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc., a commercial-stage pharmaceutical company that engages in developing and commercializing drug products. Harrow Health, Inc. owns royalty rights in four clinical stage drug candidates being developed by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in San Diego, California.

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Employees

382

IPO Date

2007-09-28

Beta

0.31

Websitewww.harrowinc.com↗